All In Biotech

Drug Trial Radar · NCT05309460

Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Apr 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Jun 20, 2022

Primary completion

May 1, 2024

Study completion Dec 1, 2024

Sponsor

Lead sponsor
Nebraska Methodist Health SystemAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.

Conditions

  • Postpartum Preeclampsia
  • Hypertension in Pregnancy

Interventions

  • Labetalol Oral TabletDrug

    See Labetalol arm.

  • NIFEdipine ERDrug

    See Nifedipine arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ReadmissionTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nebraska Methodist Women's Hospital

    Omaha, Nebraska · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.